This article is more than 5 years old. Information may no longer be current.
US thyrotropin alfa supply expected to ‘stock-out’ in July
Click Here to Manage Email Alerts
Due to unexpected delays in the release of three lots of thyrotropin alfa for injection intended for both US and global distribution, Genzyme now expects to ‘stock-out’ in the US in late July. Current stock-outs in other parts of the world are expected to persist until these lots are released.
According to the company, temporary shipment delays and regional disparities in supply availability are expected to continue for the remainder of 2011 and throughout 2012. This is a result of ongoing thyrotropin alfa for injection (Thyrogen) manufacturing capacity constraints; longer timelines to manufacture and release the drug into the market; a lack of inventory of the product; and an increase in global demand for the drug. Full details of this announcement may be found at http://www.thyrogen.com/home/thy_home.asp
The American Thyroid Association recommends that health care providers not schedule patients for thyrotropin alfa for injection use unless its availability for that patient is confirmed. Selective use of thyrotropin alfa for injection during periods of product shortage may help preserve its availability for those who may benefit from it most, according to an ATA press release.
Thyrotropin alfa is indicated for use as an adjunctive treatment for radioiodine ablation of thyroid tissue remnants in patients who have undergone a near-total or total thyroidectomy and as an adjunctive diagnostic tool for serum thyroglobulin testing with or without radioiodine imaging in the follow-up of patients with well-differentiated thyroid cancer, according to Genzyme.
 |
Follow EndocrineToday.com on Twitter. |